Tharimmune Enters Exclusive Global Licensing Agreement For Clinical Stage Asset For Chronic Pruritis
Portfolio Pulse from Benzinga Newsdesk
Tharimmune has entered into an exclusive global licensing agreement for a clinical stage asset for chronic pruritis. The company expects to complete a Phase 2 clinical trial and release topline data approximately 12 months after aligning with the FDA on trial design.
November 06, 2023 | 10:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune's new licensing agreement could potentially lead to a new product offering, pending successful clinical trials and FDA approval. This could have a positive impact on the company's stock in the short term.
The news of Tharimmune entering into an exclusive global licensing agreement for a clinical stage asset for chronic pruritis is directly related to the company's business. If the Phase 2 clinical trial is successful and the FDA approves the product, it could potentially lead to a new product offering for Tharimmune, which could increase the company's revenues and have a positive impact on its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100